DFDavid Farraday

David Farraday

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


David Farraday has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effect of Gamification Plus Automated Coaching to Increase Physical Activity Among Patients With Peripheral Artery Disease: The GAMEPAD Randomized Controlled Trial

    by Alexander C. Fanaroff, Samantha Coratti, David Farraday, Laurie Norton, Charles Rareshide, Jingsan Zhu, Michael G. Levin, Scott M. Damrauer, Jay S. Giri, Neel P. Chokshi, et al.

    Background: Supervised exercise therapy improves walking performance in patients with peripheral artery disease (PAD), but few participate. Interventions leveraging concepts from behavioral economics increase physical activity in patients at high cardiovascular risk, but barriers to physical activity differ in patients with PAD. Methods: In this randomized controlled trial, conducted from October 2020 through January 2024, patients with PAD were provided with a wearable fitness tracker, established a baseline daily step count, and set a step goal increase. They were randomly assigned to attention control or to gamification. The control group received feedback from the fitness tracker but no other interventions for 24 weeks. The gamification group was entered into a 16‐week game designed using insights from behavioral economics and received educational text messages. No intervention occurred during an 8‐week postintervention follow‐up period. Results: A total of 103 patients (mean age, 70±9 years; 54 [52%] men, 74 (72%) with exertional lower extremity symptoms) were randomized to attention control (n=52) or gamification (n=51). Compared with controls, gamification participants had a greater increase in mean daily steps from baseline during the intervention period (adjusted difference, 920 [95% CI, −22 to 1861]; P =0.06) that became statistically significant during the follow‐up period (adjusted difference, 1074 [95% CI, 133–2015]; P =0.03). Conclusions: In this randomized clinical trial, gamification increased physical activity compared with attention control over a 24‐week follow‐up. This intervention may represent a scalable approach for increasing physical activity in patients with PAD who are not able to participate in supervised exercise therapy. Registration: URL: https://clinicaltrials.gov/study/NCT04536012 ; Unique Identifier: NCT04536012.


  • Cost-Effectiveness of Gamification, Financial Incentives, or Both to Increase Physical Activity Among Patients With Elevated Risk for Cardiovascular Disease

    by Louise B. Russell, Kevin G.M. Volpp, Mitesh S. Patel, Neel P. Chokshi, Samantha Coratti, David Farraday, Laurie Norton, Charles Rareshide, Jingsan Zhu, Tamar Klaiman, et al.

    BACKGROUND: The BE ACTIVE trial (Behavioral Economic Approaches to Increase Physical Activity Among Patients with Elevated Risk for Cardiovascular Disease) documented the effectiveness, compared with an attention control arm that received daily text messages, of gamification, financial incentives, or gamification+financial incentives to increase steps/day. Increases in daily step count are associated with longer life expectancy, but understanding the cost-effectiveness of these interventions is essential for payers and other stakeholders seeking to implement findings. METHODS: We built a probabilistic Markov model to compare intervention costs with lifetime estimates of life-years and quality-adjusted life-years for 2 sets of comparisons: (1) each behavioral intervention versus attention control, and (2) each trial arm, including attention control, versus no intervention. Since the durability of changes in steps/day post-intervention is unknown, we modeled optimistic, intermediate, and pessimistic scenarios. RESULTS: Over the 12-month intervention, per-participant cost to deliver attention control was $878, gamification $938, financial incentives $1534, and gamification+financial incentives $1712. Compared with attention control, gamification’s cost-effectiveness ranged from $261 (95% CI, 259–263) per life-year gained if mean steps/day during the last 18 weeks of follow-up are maintained (optimistic), to $30 550 (95% CI, 30 503–30 597) per life-year if steps/day continue to decline at the rate observed during the full 26-week follow-up (pessimistic). Gamification+financial incentives cost <$50 000/life-year only under the optimistic and intermediate scenarios. Financial incentives was dominated by gamification and gamification+financial incentives. When all 4 trial arms, including attention control, were compared with no intervention, gamification again cost <$50 000/life-year across all durability scenarios. CONCLUSIONS: Across a range of scenarios about the durability of increases in steps/day post-intervention, gamification consistently cost <$50 000 per life-year gained, the threshold for high value interventions set by American College of Cardiology/American Heart Association guidelines. Gamification+financial incentives was high-value except in the pessimistic scenario. Financial incentives was dominated. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03911141.